Epsilogen is a Biotech company based in London, United Kingdom. It has raised $60M in total funding. Latest round: Series B. Backed by Epidarex Capital.
Epsilogen funding overview
Epsilogen is a Biotech company based in London, United Kingdom. Epsilogen has raised $60M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in September 2024. The round record for Epsilogen runs through 2024; nothing later has been disclosed. Investors on record include Epidarex Capital.
Epsilogen at a glance
Total raised
$60M
Latest round
Series B
Latest round date
September 2024
Industry
Biotech
Headquarters
London, United Kingdom
Notable investors
Epidarex Capital
Frequently asked about Epsilogen funding
How much has Epsilogen raised?
Epsilogen has raised $60M in total disclosed funding across the rounds on record.
Who has invested in Epsilogen?
Epidarex Capital are named among the investors backing Epsilogen.
What was the latest Epsilogen funding round?
The most recent disclosed round is a Series B, announced in September 2024.
Where is Epsilogen based?
Epsilogen is based in London, United Kingdom.
What sector does Epsilogen operate in?
Epsilogen is tracked under Biotech from London, United Kingdom, with $60M in disclosed funding.
When did Epsilogen last raise?
The last disclosed Epsilogen round closed in September 2024 at Series B.
We update the Epsilogen record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related Biotech companies in London and their backers are listed below.
